BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/21/2024 3:14:32 AM | Browse: 81 | Download: 239
 |
Received |
|
2024-02-29 23:00 |
|
Peer-Review Started |
|
2024-02-29 23:00 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-04-13 19:20 |
|
Revised |
|
2024-05-08 22:15 |
|
Second Decision |
|
2024-05-24 02:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-05-24 06:08 |
|
Articles in Press |
|
2024-05-24 06:08 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-29 09:16 |
|
Publish the Manuscript Online |
|
2024-06-21 03:14 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jakub Rochoń, Piotr Kalinowski, Ksenia Szymanek-Majchrzak and Michał Grąt |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Piotr Kalinowski, MD, PhD, Associate Professor, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Banacha 1a st, Warsaw 02-097, Poland. piotr.kalinowski@wum.edu.pl |
| Key Words |
Metabolic dysfunction-associated fatty liver disease; Metabolic dysfunction-associated steatohepatitis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Metabolic syndrome; Obesity; Gastrointestinal microbiota; Glucagon-like peptide-1; Glucagon-like peptide-2; Bariatric surgery |
| Core Tip |
Dysbiosis of gut microbiota leading to gut-liver axis disruption is a significant contributor to the development of metabolic dysfunction-associated fatty liver disease (MAFLD). However, the precise role of enteric bacteria in the pathogenesis of MAFLD remains unclear. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may modulate MAFLD progression mechanisms to alleviate dysfunction, partly by modifying gut microbiota. The association between MAFLD pathogenesis and gut microbiota dysbiosis needs to be understood, as well as how GLP-1 RAs can regulate these impaired mechanisms and improve patient outcomes. |
| Publish Date |
2024-06-21 03:14 |
| Citation |
<p>Rochoń J, Kalinowski P, Szymanek-Majchrzak K, Grąt M. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. <i>World J Gastroenterol</i> 2024; 30(23): 2964-2980</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i23/2964.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i23.2964 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
